This section is intended for patients prescribed ADCETRIS. If you are a member of the public click here. If you are a UK healthcare professional click here.

Receiving ADCETRIS(brentuximab vedotin)1,2

How is brentuximab vedotin given?

Brentuximab vedotin is given to you by your doctor or nurse as an infusion into a vein (intravenously). The infusion takes 30 minutes and you will be monitored during and after the procedure.

How often will I receive my dose?

Brentuximab vedotin will be given to you once every three weeks for up to one year (up to 16 cycles of treatment).

The amount you receive depends on your body weight, as the recommended dose is 1.8 mg per kg of body weight (or 1.8 mg/kg).

The dose you receive may be reduced down to 1.2mg/kg if you have kidney or liver problems or to help manage some side effects.

Your doctor will perform regular blood tests to make sure that it is safe for you to receive this medicine.

Is there anything else I should tell my doctor when I am given brentuximab vedotin?

When you are first given brentuximab vedotin and during or in between cycles of treatment, tell your doctor if you:

  • Are taking, or have previously taken, medicines which may affect your immune system, such as chemotherapy or immunosuppressive agents
  • Have, or think you have, an infection. Some infections may be serious and can be due to viruses, bacteria or other causes that may be life-threatening
  • Have new or worsening shortness of breath or cough as these may be symptoms of a potentially fatal lung complication (pulmonary toxicity)
  • Experience a whistling sound during breathing (wheezing), difficulty breathing, hives, itching or swelling
  • Have severe and persistent stomach pain, with or without nausea and vomiting, as these may be symptoms of a serious and potentially fatal condition known as pancreatitis (inflammation of the pancreas)
  • Have any problems with a change in the sensitivity of the skin, especially in the hands or feet, such as numbness, tingling, a burning sensation, pain, discomfort or weakness
  • Have headaches, feel tired, experience dizziness, look pale (anaemia), or have unusual bleeding or bruising under the skin, longer than usual bleeding after your blood has been drawn or bleeding from your gums
  • Develop chills or shivering or feel warm; you should also take your temperature as you may have a fever
  • Experience dizziness, decreased urination, confusion, vomiting, nausea, swelling, shortness of breath or heart rhythm disturbances
  • Experience flu-like symptoms followed by a painful red or purplish rash that spreads and blisters
  • Have new or worsening stomach pain, nausea, vomiting, constipation
  • Feel tired, have frequent urination, increased thirst, increased appetite with unintended weight loss, or irritability
  • Have kidney or liver problems or have abnormal liver test results

Information and support

Adcetris Patients Guide

ADCETRIS Patient Booklet

Takeda Oncology has developed this booklet providing information for patients who have been prescribed brentuximab vedotin for Hodgkin lymphoma (HL) or systemic Anaplastic Large Cell Lymphoma (sALCL).

Adcetris Management Tracker

Peripheral Neuropathy Diary

Takeda Oncology has developed this diary for you to print, and record your symptoms, in particular symptoms related to peripheral neuropathy. This information can be shared with your healthcare professional to help you to continue with your brentuximab vedotin treatment.

Reporting of side effects

ADCETRIS (brentuximab vedotin) is subject to additional monitoring. This will allow quick identification of new safety information.
You can help by reporting any side effects you may get. If you get any side effects whilst taking ADCETRIS, talk to your doctor, pharmacist or nurse.
This includes any possible side effects not listed on this website or in the patient information leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/. By reporting side effects you can help provide more information on the safety of this medicine.